Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Luye Pharma Group ( (HK:2186) ) has issued an update.
Luye Pharma Group announced the completion of patient enrollment for a Phase 3 clinical trial of Ruoxinlin® in China, aimed at treating Generalized Anxiety Disorder (GAD). This trial could position Ruoxinlin® as the first serotonin, norepinephrine, and dopamine reuptake inhibitor approved for anxiety treatment globally, addressing a significant unmet need due to the lack of new anxiety drugs over the past 15 years. The successful trial and subsequent approval could enhance Luye Pharma’s market position and offer a new treatment option for millions of anxiety sufferers in China.
The most recent analyst rating on (HK:2186) stock is a Hold with a HK$3.13 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
More about Luye Pharma Group
Luye Pharma Group is a pharmaceutical company focused on developing innovative drugs, particularly in the central nervous system (CNS) sector. The company has a strong market presence in China and internationally, with products approved in the U.S., Europe, Japan, and other regions. Its portfolio includes drugs for mental health disorders such as Major Depressive Disorder and anxiety.
YTD Price Performance: 75.12%
Average Trading Volume: 111,824,541
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.33B
For detailed information about 2186 stock, go to TipRanks’ Stock Analysis page.